SVF
Level D· Preclinical EvidenceAnimal Study

Low Intensity Ultrasound-facilitated exosome delivery promotes hippocampal neurogenesis in Alzheimer's disease.

Yan Y., Su J., Xie M., Kong Y., Wang C., Yuan G.

Animal Study with a reported sample of 6 on Neuroinflammation, published in Brain Stimul (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Brain Stimul (2026)
Country
United States
Reported sample size
6
PMID
41482153
DOI
10.1016/j.brs.2025.103015

Abstract (original English)

Low-intensity ultrasound (LIUS) and human adipose-tissue mesenchymal stem cell-derived exosomes (hADSC-Exos) have shown neuroprotective potential, but their combined effects in Alzheimer's disease (AD) remain unclear. To evaluate the safety and efficacy of intranasal hADSC-Exos alone or combined with LIUS in APP/PS1 mice, and explore underlying molecular mechanisms. Female APP/PS1 mice (30 weeks) were randomized into five groups (n = 6). Treatments included intranasal hADSC-Exos, LIUS, or both for 2 months. Behavioral tests, histology, and hippocampal RNA-seq were performed. LIUS enhanced Exo uptake in HT22 cells by ∼8 % without toxicity. Combined treatment improved learning and memory (escape latency ↓45 s→20 s; P < 0.01), increased neurogenesis markers (GFAP/SOX2, DCX, Ki67), and reduced amyloid and microglial activation. RNA-seq identified 93 specific DEGs in the combination group, with enrichment in synaptic and mitochondrial pathways. Fos and Kcnj13 were top DEGs and both downregulated after therapy (P < 0.05). Intranasal hADSC-Exos combined with LIUS is safe, enhances brain delivery, and synergistically improves cognition and neurogenesis in AD mice. The Fos-Kcnj13 axis may mediate these effects, suggesting a promising noninvasive therapeutic strategy.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
Alzheimer DiseaseAnimalsNeurogenesisHippocampusExosomesMiceFemaleUltrasonic WavesHumansMice, Transgenic
HipNeuroinflammation
View on PubMedDOI

Related research